HuGE Literature Finder
|
||
Records 1-41
|
High frequency of H3K27M immunopositivity in adult thalamic glioblastoma.
Neuropathology : official journal of the Japanese Society of Neuropathology 2019 Apr 39 (2): 78-84. Rao Shilpa, Kanuri Nandaki N, Nimbalkar Vidya, Arivazhagan Arimappamagan, Santosh Va |
|
Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
Pathology, research and practice 2018 Apr . Kim Hyun Sik, Kwon Mi Jung, Song Joon Ho, Kim Eun Soo, Kim Ho Young, Min Kyueng-Wh |
|
Clinical prognostic value of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in glioblastoma.
Journal of neuro-oncology 2018 Feb . Mistry Akshitkumar M, Vnencak-Jones Cindy L, Mobley Bret |
|
Correlations of MGMT genetic polymorphisms with temozolomide resistance and prognosis of patients with malignant gliomas: a population-based study in China.
Cancer gene therapy 2017 Apr . Wang H-W, Xu Z-K, Song Y, Liu Y |
|
IDH mutation and MGMT promoter methylation are associated with the pseudoprogression and improved prognosis of glioblastoma multiforme patients who have undergone concurrent and adjuvant temozolomide-based chemoradiotherapy.
Clinical neurology and neurosurgery 2016 Oct 151 31-36. Li Hailong, Li Jiye, Cheng Gang, Zhang Jianning, Li Xuezh |
|
GBM-associated mutations and altered protein expression are more common in young patients.
Oncotarget 2016 Aug . Ferguson Sherise D, Xiu Joanne, Weathers Shiao-Pei, Zhou Shouhao, Kesari Santosh, Weiss Stephanie E, Verhaak Roeland G, Hohl Raymond J, Barger Geoffrey R, Reddy Sandeep K, Heimberger Amy |
|
Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Neuro-oncology 2016 Aug . Nguyen HuyTram N, Lie Amy, Li Tie, Chowdhury Reshmi, Liu Fei, Ozer Byram, Wei Bowen, Green Richard M, Ellingson Benjamin M, Wang He-Jing, Elashoff Robert, Liau Linda M, Yong William H, Nghiemphu Phioanh L, Cloughesy Timothy, Lai Albe |
|
Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma.
Oncotarget 2016 Jul . Schiffgens Salveena, Wilkens Ludwig, Brandes Alba A, Meier Tatiana, Franceschi Enrico, Ermani Mario, Hartmann Christian, Sandalcioglu I Erol, Dumitru Claudia |
|
Polymorphisms in DNA Repair Gene and Susceptibility to Glioma: A Systematic Review and Meta-Analysis Based on 33 Studies with 15 SNPs in 9 Genes.
Cellular and molecular neurobiology 2016 Apr . Liu Kun, Jiang Yuga |
|
Assessment of Quantitative and Allelic MGMT Methylation Patterns as a Prognostic Marker in Glioblastoma.
Journal of neuropathology and experimental neurology 2016 Feb . Kristensen Lasse S, Michaelsen Signe R, Dyrbye Henrik, Aslan Derya, Grunnet Kirsten, Christensen Ib J, Poulsen Hans S, Grønbæk Kirsten, Broholm Hel |
|
Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach.
Journal of clinical pathology 2016 Jan . Rajmohan K S, Sugur Harsha S, Shwetha S D, Ramesh Arvind, Thennarasu Kandavel, Pandey Paritosh, Arivazhagan Arimappamagan, Santosh Va |
|
A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
Acta neuropathologica communications 2016 4 (1): 79. Arita Hideyuki, Yamasaki Kai, Matsushita Yuko, Nakamura Taishi, Shimokawa Asanao, Takami Hirokazu, Tanaka Shota, Mukasa Akitake, Shirahata Mitsuaki, Shimizu Saki, Suzuki Kaori, Saito Kuniaki, Kobayashi Keiichi, Higuchi Fumi, Uzuka Takeo, Otani Ryohei, Tamura Kaoru, Sumita Kazutaka, Ohno Makoto, Miyakita Yasuji, Kagawa Naoki, Hashimoto Naoya, Hatae Ryusuke, Yoshimoto Koji, Shinojima Naoki, Nakamura Hideo, Kanemura Yonehiro, Okita Yoshiko, Kinoshita Manabu, Ishibashi Kenichi, Shofuda Tomoko, Kodama Yoshinori, Mori Kanji, Tomogane Yusuke, Fukai Junya, Fujita Koji, Terakawa Yuzo, Tsuyuguchi Naohiro, Moriuchi Shusuke, Nonaka Masahiro, Suzuki Hiroyoshi, Shibuya Makoto, Maehara Taketoshi, Saito Nobuhito, Nagane Motoo, Kawahara Nobutaka, Ueki Keisuke, Yoshimine Toshiki, Miyaoka Etsuo, Nishikawa Ryo, Komori Takashi, Narita Yoshitaka, Ichimura Koic |
|
The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival.
Carcinogenesis 2015 Dec . Fogli Anne, Chautard Emmanuel, Vaurs-Barrière Catherine, Pereira Bruno, Müller-Barthélémy Mélanie, Court Franck, Biau Julian, Almeida Pinto Afonso, Kémény Jean-Louis, Khalil Toufic, Karayan-Tapon Lucie, Verrelle Pierre, Costa Bruno Marques, Arnaud Philip |
|
Genetic and epigenetic characterization of low-grade gliomas reveals frequent methylation of the MLH3 gene.
Genes, chromosomes & cancer 2015 Nov 54 (11): 655-67. Lhotska Halka, Zemanova Zuzana, Cechova Hana, Ransdorfova Sarka, Lizcova Libuse, Kramar Filip, Krejcik Zdenek, Svobodova Karla, Bystricka Dagmar, Hrabal Petr, Dohnalova Alena, Michalova Ky |
|
TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
Oncotarget 2015 Nov . Gao Ke, Li Gang, Qu Yiping, Wang Maode, Cui Bo, Ji Meiju, Shi Bingyin, Hou Pe |
|
TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
Journal of neuro-oncology 2015 Nov . Nencha Umberto, Rahimian Amithys, Giry Marine, Sechi Andrea, Mokhtari Karima, Polivka Marc, Schmitt Yohann, Di Stefano Anna-Luisa, Alentorn Agusti, Labussière Marianne, Sanson Ma |
|
ATRX loss in adult supratentorial diffuse astrocytomas correlates with p53 over expression and IDH1 mutation and predicts better outcome in p53 accumulated patients.
Histology and histopathology 2015 Sep 11664. Shao Li-Wei, Pan Yi, Qi Xue-Ling, Li Yong-Xiao, Ma Xiao-Long, Yi Wei-Ning, Zhang Jing, Zhong Yan-Feng, Chang Qi |
|
Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.
Neuro-oncology 2015 Sep . Dubbink Hendrikus J, Atmodimedjo Peggy N, Kros Johan M, French Pim J, Sanson Marc, Idbaih Ahmed, Wesseling Pieter, Enting Roelien, Spliet Wim, Tijssen Cees, Dinjens Winand N M, Gorlia Thierry, van den Bent Martin |
|
Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Neuro-oncology 2015 Sep 17 (9): 1231-40. Spiegl-Kreinecker Sabine, Lötsch Daniela, Ghanim Bahil, Pirker Christine, Mohr Thomas, Laaber Magdalena, Weis Serge, Olschowski Alfred, Webersinke Gerald, Pichler Josef, Berger Walt |
|
Immunohistochemical profiles of IDH1, MGMT and P53: practical significance for prognostication of patients with diffuse gliomas.
Neuropathology : official journal of the Japanese Society of Neuropathology 2015 Aug 35 (4): 324-35. Ogura Ryosuke, Tsukamoto Yoshihiro, Natsumeda Manabu, Isogawa Mizuho, Aoki Hiroshi, Kobayashi Tsutomu, Yoshida Seiichi, Okamoto Kouichiro, Takahashi Hitoshi, Fujii Yukihiko, Kakita Akiyos |
|
Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers.
Acta neuropathologica 2015 May 129 (5): 669-78. Korshunov Andrey, Ryzhova Marina, Hovestadt Volker, Bender Sebastian, Sturm Dominik, Capper David, Meyer Jochen, Schrimpf Daniel, Kool Marcel, Northcott Paul A, Zheludkova Olga, Milde Till, Witt Olaf, Kulozik Andreas E, Reifenberger Guido, Jabado Nada, Perry Arie, Lichter Peter, von Deimling Andreas, Pfister Stefan M, Jones David T |
|
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide.
Neuro-oncology 2015 Apr . Rapkins Robert W, Wang Fan, Nguyen HuyTram N, Cloughesy Timothy F, Lai Albert, Ha Wendy, Nowak Anna K, Hitchins Megan P, McDonald Kerrie |
|
[IDH1 mutation and MGMT expression in astrocytoma and the relationship with prognosis after radiotherapy].
Zhonghua bing li xue za zhi Chinese journal of pathology 2014 Oct 43 (10): 668-72. Jiang Mengwan, Dong Xianghui, Li Jiayao, Li Jingqi, Qi Jipi |
|
Association between DNA repair gene polymorphisms and risk of glioma: a systematic review and meta-analysis.
Neuro-oncology 2014 Jun 16 (6): 807-14. Adel Fahmideh Maral, Schwartzbaum Judith, Frumento Paolo, Feychting Mar |
|
Correlation of IDH1/2 mutation with clinicopathologic factors and prognosis in anaplastic gliomas: a report of 203 patients from China.
Journal of cancer research and clinical oncology 2014 Jan 140 (1): 45-51. Zhang Chuan-Bao, Bao Zhao-Shi, Wang Hong-Jun, Yan Wei, Liu Yan-Wei, Li Ming-Yang, Zhang Wei, Chen Ling, Jiang T |
|
Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
Asian Pacific journal of cancer prevention : APJCP 2014 15 (24): 10893-8. Wang Kai, Wang Yin-Yan, Ma Jun, Wang Jiang-Fei, Li Shao-Wu, Jiang Tao, Dai Jian-Pi |
|
The T genotype of the MGMT C>T (rs16906252) enhancer single-nucleotide polymorphism (SNP) is associated with promoter methylation and longer survival in glioblastoma patients.
European journal of cancer (Oxford, England : 1990) 2013 Jan 49 (2): 360-8. McDonald K L, Rapkins R W, Olivier J, Zhao L, Nozue K, Lu D, Tiwari S, Kuroiwa-Trzmielina J, Brewer J, Wheeler H R, Hitchins M |
|
The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas.
Journal of neuro-oncology 2012 Dec 110 (3): 325-33. Juratli T A, Kirsch M, Geiger K, Klink B, Leipnitz E, Pinzer T, Soucek S, Schrock E, Schrok E, Schackert G, Krex |
|
IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
Cancer science 2012 Feb 103 (2): 269-73. SongTao Qi, Lei Yu, Si Gui, YanQing Ding, HuiXia Han, XueLin Zhang, LanXiao Wu, Fei Y |
|
Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis.
Journal of neuro-oncology 2011 Nov 105 (2): 325-35. Olson Robert A, Brastianos Priscilla K, Palma David |
|
Benefits of interferon-? and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
Cancer 2011 Apr 117 (8): 1721-30. Motomura Kazuya, Natsume Atsushi, Kishida Yugo, Higashi Hiroyuki, Kondo Yutaka, Nakasu Yoko, Abe Tatsuya, Namba Hiroki, Wakai Kenji, Wakabayashi Toshihi |
|
First-line temozolomide chemotherapy in progressive low-grade astrocytomas after radiotherapy: molecular characteristics in relation to response.
Neuro-oncology 2011 Feb 13 (2): 235-41. Taal Walter, Dubbink Hendrikus J, Zonnenberg Chris B L, Zonnenberg Bernard A, Postma Tjeerd J, Gijtenbeek Johanna M M, Boogerd Willem, Groenendijk Floris H, Kros Johan M, Kouwenhoven Mathilde C M, van Marion Ronald, van Heuvel Irene, van der Holt Bronno, Bromberg Jacoline E C, Sillevis Smitt Peter A E, Dinjens Winand N M, van den Bent Martin J, |
|
Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: one step forward, and one step back?
Radiation oncology (London, England) 2011 6 (1): 115. Combs Stephanie E, Rieken Stefan, Wick Wolfgang, Abdollahi Amir, von Deimling Andreas, Debus Jürgen, Hartmann Christi |
|
DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma.
Neuro-oncology 2010 Jan 12 (1): 37-48. Rajaraman Preetha, Hutchinson Amy, Wichner Sara, Black Peter M, Fine Howard A, Loeffler Jay S, Selker Robert G, Shapiro William R, Rothman Nathaniel, Linet Martha S, Inskip Peter |
|
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.
Neuro-oncology 2009 Dec 11 (6): 825-32. Armstrong Terri S, Cao Yumei, Scheurer Michael E, Vera-Bolaños Elizabeth, Manning Rochelle, Okcu Mehmet F, Bondy Melissa, Zhou Renke, Gilbert Mark |
|
Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009 Nov 15 (21): 6683-93. Felsberg Jörg, Rapp Marion, Loeser Simon, Fimmers Rolf, Stummer Walter, Goeppert Matthias, Steiger Hans-Jacob, Friedensdorf Britta, Reifenberger Guido, Sabel Michael |
|
Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.
Cancer investigation 2009 Oct 27 (8): 825-9. Shamsara Jamal, Sharif Samaneh, Afsharnezhad Sima, Lotfi Marzieh, Raziee Hamid Reza, Ghaffarzadegan Kamran, Moradi Afshin, Rahighi Saeed, Behravan Jav |
|
Association and interactions between DNA repair gene polymorphisms and adult glioma.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2009 Jan 18 (1): 204-14. Liu Yanhong, Scheurer Michael E, El-Zein Randa, Cao Yumei, Do Kim-Anh, Gilbert Mark, Aldape Kenneth D, Wei Qingyi, Etzel Carol, Bondy Melissa |
|
Promoter methylation and polymorphisms of the MGMT gene in glioblastomas: a population-based study.
Neuroepidemiology 2009 32 (1): 21-9. Zawlik Izabela, Vaccarella Salvatore, Kita Daisuke, Mittelbronn Michel, Franceschi Silvia, Ohgaki Hiro |
|
DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas.
Neuroepidemiology 2007 29 (1-2): 55-8. Felini Martha J, Olshan Andrew F, Schroeder Jane C, North Kari E, Carozza Susan E, Kelsey Karl T, Liu Mei, Rice Terri, Wiencke John K, Wrensch Margaret |
|
A genotype of the polymorphic DNA repair gene MGMT is associated with de novo glioblastoma.
Neurological research 2003 Dec 25 (8): 875-9. Inoue Ryo, Isono Mitsuo, Abe Masako, Abe Tatsuya, Kobayashi Hideno |
- Page last reviewed:Mar 1, 2018
- Page last updated:Jun 20, 2019
- Content source: